Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Parker Institute

- PMLiVE

LEO Pharma receives NICE approval for chronic hand eczema cream

The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

- PMLiVE

Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education

UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...

Medscape Education

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

The cream is now the first treatment approved by the regulator specifically for this patient population

- PMLiVE

Honoring the Legacy of Dr. Robert Sidbury, MD, MPH

We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...

Medscape Education

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery

Approximately 500,000 people worldwide are affected by the rare genetic skin disorders

- PMLiVE

LEO Pharma and the Parker Institute join forces to advance dermatology research

The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

There is currently no cure for the group of rare inherited skin disorders

- PMLiVE

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links